After years of delays and rising costs, AstraZeneca has formally unveiled ... In 2019, it was reported that the cost of building the DISC had swelled to around $1 billion – twice the original ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca. Perhaps that’s why, in a wood-paneled conference room at the St. Regis ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

May 30 (Reuters) - Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Smile Group, a technology investor and operator, has appointed Gagandeep Singh Bedi, former managing director at AstraZeneca Pharma India, as managing partner to lead its new healthtech venture ...

It causes up to 45,000 premature deaths each year and places a significant burden on the healthcare system. AstraZeneca welcomed NICE’s decision, which expands access beyond previous eligibility ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the ...